BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14509872)

  • 1. Determinants of health-related quality of life in HIV-infected patients.
    Murri R; Fantoni M; Del Borgo C; Visona R; Barracco A; Zambelli A; Testa L; Orchi N; Tozzi V; Bosco O; Wu AW
    AIDS Care; 2003 Aug; 15(4):581-90. PubMed ID: 14509872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
    Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda.
    Stangl AL; Wamai N; Mermin J; Awor AC; Bunnell RE
    AIDS Care; 2007 May; 19(5):626-36. PubMed ID: 17505923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.
    Siddiqui U; Bini EJ; Chandarana K; Leong J; Ramsetty S; Schiliro D; Poles M
    J Clin Gastroenterol; 2007; 41(5):484-90. PubMed ID: 17450031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.
    Kempen JH; Martin BK; Wu AW; Barron B; Thorne JE; Jabs DA;
    Ophthalmology; 2003 May; 110(5):987-95. PubMed ID: 12750102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda.
    Bajunirwe F; Tisch DJ; King CH; Arts EJ; Debanne SM; Sethi AK
    AIDS Care; 2009 Mar; 21(3):271-9. PubMed ID: 19280404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART.
    Tozzi V; Balestra P; Murri R; Galgani S; Bellagamba R; Narciso P; Antinori A; Giulianelli M; Tosi G; Fantoni M; Sampaolesi A; Noto P; Ippolito G; Wu AW
    Int J STD AIDS; 2004 Apr; 15(4):254-9. PubMed ID: 15075020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and associated factors in people with HIV: an Irish cohort study.
    George S; Bergin C; Clarke S; Courtney G; Codd MB
    Health Qual Life Outcomes; 2016 Aug; 14(1):115. PubMed ID: 27495166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.
    Préau M; Leport C; Salmon-Ceron D; Carrieri P; Portier H; Chene G; Spire B; Choutet P; Raffi F; Morin M
    AIDS Care; 2004 Jul; 16(5):649-61. PubMed ID: 15223534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evidence-based medicine and the validation of quality-of-life questionnaires: the Spanish version of the MOS-HIV questionnaire for the evaluation of the quality of life in patients infected by HIV].
    Badía X; Podzamczer D; López-Lavid C; García M
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():103-13. PubMed ID: 10605195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.